2,3-dibenzylbutane-1,4-diol has been researched along with 4-butyrolactone in 1 studies
| Studies (2,3-dibenzylbutane-1,4-diol) | Trials (2,3-dibenzylbutane-1,4-diol) | Recent Studies (post-2010) (2,3-dibenzylbutane-1,4-diol) | Studies (4-butyrolactone) | Trials (4-butyrolactone) | Recent Studies (post-2010) (4-butyrolactone) |
|---|---|---|---|---|---|
| 8 | 0 | 0 | 4,456 | 78 | 1,823 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukuoka, K; Hirano, T; Hosaka, K; Matsumoto, Y; Mitsuhashi, H; Naito, T; Oka, K | 1 |
1 other study(ies) available for 2,3-dibenzylbutane-1,4-diol and 4-butyrolactone
| Article | Year |
|---|---|
Antiproliferative activity of mammalian lignan derivatives against the human breast carcinoma cell line, ZR-75-1.
Topics: 4-Butyrolactone; Adenosine Triphosphatases; Animals; Benzyl Compounds; Breast Neoplasms; Butylene Glycols; Cell Division; Cell Line; Dogs; Dose-Response Relationship, Drug; Fluorouracil; Humans; Kidney Cortex; Lethal Dose 50; Lignans; Ouabain | 1990 |